Cyclophosphamide

Buy now to access the full article, existing subscribers login

Sections available in full article Name, Class of drug, Description, Uses, Administration, Routes of administration, Dosage, Pharmocokinetics, Pathological variations, Precautions, Contra-indications, Use with care, Interactions, Adverse reactions, Sources, Publications, Vetstream contributor(s),
Contributors Dr William Brewer Jr DVM DiplACVIM Oncology and Internal Medicine
Dr Laura Garrett DVM DACVIM (Oncology)

Name

  • Cyclophosphamide.

Class of drug

  • Nitrogen mustard group.

Uses

Action

  • Antineoplastic cytotoxic immunosuppressive alkylating agent  Chemotherapy: general principles  .

Indications

  • Lymphoproliferative disease  Lymphoproliferative disease  .
  • Myeloproliferative disease.
  • Sarcoma  Sarcoma   Post-vaccinational sarcoma   Synovial sarcoma  , carcinoma  Squamous cell carcinoma   Adenoma  adenocarcinoma  .
  • Immune-mediated diseases  Immune-mediated thrombocytopenia   Anemia: immune-mediated hemolytic  .

Adverse reactions

Other reported reactions

  • Myelosuppression, with the nadir usually occurring 7-14 days after the start of therapy.
  • Sterile hemorrhagic cystitis (the risk may be reduced by increasing water consumption and ensuring adequate urine flow) - rare complication in cats. 
  • Vomiting.
  • Diarrhea.
  • Reduction in hair growth rate.

Treatment

Myelosuppression
  • Regular monitoring of neutrophil is recommended. Adjust dose as necessary.
  • Prophylactic antibiotics when neutrophil count <1000.

Sterile hemorrhagic cystitis

  • The risk may be reduced by increasing water consumption and inducing polyuria.
  • Administer in morning to allow animal to urinate out of bladder, evening dosing increases dwell time of toxic metabolite (acrolein) in bladder as animal sleeps.
  • Administer furosemide  Furosemide   concurrently to increase urine production and therefore dilution and excretion of the toxic metabolite.

Treatment

  • Discontinue cyclophosphamide.
  • Treat concurrent UTI.
  • Increase fluid intake possibly with use of furosemide.
  • Possible use of anti-inflammatory doses of corticosteroids.
  • Intracavitary instillation of formalin or DMSO in cases that do not respond to above therapies after 2-3 months.

Sample content only, to unlock the full article login or buy now

Loading...